| 1. Domain | 1.1 Scope of the Domain | Boundaries | The range of phenomena the science includes and excludes. | Focuses on how cells grow, replicate DNA, divide, differentiate, arrest, senesce, or undergo programmed or unprogrammed death. Includes cell-cycle regulation, checkpoint control, mitosis/meiosis, stem-cell fate decisions, lineage restriction, apoptosis, necroptosis, autophagy-dependent death, and senescence. Excludes organism-level aging, whole-tissue development, or immune-mediated cell elimination unless directly tied to intrinsic cellular decision mechanisms. |
| | Scale | The spatial, temporal, or organizational level at which the science operates (e.g., quantum, cellular, social, cosmic). | Operates across spatial scales from molecular regulators (nm) to entire cells (µm). Temporal scales range from seconds (checkpoint signaling) to hours (cycle phases) to days or weeks for differentiation and senescence progression. |
| 1.2 Ontological Commitments | Entities | The kinds of things assumed to exist within the domain (particles, organisms, agents, fields, etc.). | Cyclins, CDKs, checkpoints, DNA replication complexes, spindle machinery, apoptotic proteins (caspases, BCL-2 family), necroptotic machinery (RIPK1/3, MLKL), autophagy regulators, transcription factors controlling lineage fate, chromatin states, cell-identity markers. |
| | Properties | The fundamental attributes these entities possess (mass, charge, genotype, preference, etc.). | Proliferative capacity, checkpoint sensitivity, differentiation potential, chromatin accessibility, metabolic state, DNA integrity, damage load, apoptotic threshold, mitochondrial outer-membrane permeabilization sensitivity, lineage-specific transcriptional signatures. |
| | Categories | The basic ontological types used to classify domain elements (substances, processes, relations, structures). | Cell-cycle phases (G1, S, G2, M), fate states (stem, progenitor, differentiated), death modalities (apoptosis, necroptosis, autophagy-associated death), checkpoint types (G1/S, G2/M, spindle assembly), lineage-commitment modes (binary, graded, stochastic). |
| 1.3 State-Variables | Variables | The measurable or definable properties that describe system conditions. | Cyclin levels, CDK activity, DNA damage counts, replication completion status, checkpoint activation state, chromatin marks, transcription-factor levels, mitochondrial integrity, caspase activity, cell-identity marker expression. |
| | Parameterization | How variables encode and represent the system’s state. | Parameterized by kinetic profiles of cyclin/CDK oscillations, DNA integrity metrics, transcriptional state vectors, chromatin-state maps, apoptotic activation thresholds, lineage-bias probability distributions, and mitochondrial depolarization curves. |
| 1.4 Admissible Idealizations | Simplifications | Conceptual reductions used to make the domain tractable (point masses, rational agents, perfect gases). | Treating cell-cycle phases as discrete blocks; reducing fate decisions to binary choices; modeling apoptosis as a sharp on/off switch; simplifying chromatin states into coarse categories; treating checkpoint signals as instantaneous; ignoring spatial heterogeneity within the cell. |
| | Validity Conditions | The limits and contexts in which idealizations hold or break down. | Idealizations fail when transitions are graded rather than discrete, when chromatin or transcription states are highly heterogeneous, when non-canonical death pathways dominate, or when signaling noise heavily influences lineage decisions. |
| 1.5 Domain Assumptions | Structural Assumptions | Background ontological stances such as determinism, continuity, randomness, discreteness. | Cell-cycle progression is cyclic and regulated; checkpoints maintain genomic integrity; differentiation is governed by regulatory networks; cell death follows conserved biochemical pathways; fate decisions integrate intrinsic and extrinsic signals coherently. |
| | Implicit Commitments | Unstated but necessary assumptions that shape the field’s conceptual structure. | Assumes regulatory networks remain functional, DNA repair is reliable, checkpoint sensors are accurate, apoptosis machinery responds predictably, and chromatin landscapes are sufficiently stable to support consistent fate outcomes. |
| 1.6 Internal Coherence Requirements | Consistency | The demand that domain concepts do not contradict one another. | DNA replication, checkpoint signaling, mitotic mechanics, fate-decision logic, and death machinery must not contradict one another; lineage-commitment models must align with chromatin accessibility and transcriptional dynamics. |
| | Compatibility | The requirement that entities, variables, and assumptions fit together into a unified descriptive framework. | Cyclins/CDKs, checkpoints, transcriptional regulators, chromatin states, mitochondrial signals, and apoptotic/necroptotic machinery must integrate into a single coherent framework governing proliferation, identity, and survival. |
| 2. Evidence Layer | 2.1 Observable Phenomena | Observables | The aspects of the domain that can produce detectable signals accessible to measurement. | Cyclin oscillations, checkpoint activation, DNA replication progression, chromosome condensation, spindle assembly, caspase activation, mitochondrial outer-membrane permeabilization, chromatin-state transitions, lineage-marker expression, senescence-associated phenotypes. |
| | Detection Limits | The boundaries of what can be resolved or sensed by current instruments or methods. | Limited by spatial resolution (~200 nm optical; ~20–50 nm super-resolution; ~1–2 nm EM), temporal speed of detection (ms for Ca²⁺/checkpoints; minutes–hours for transitions), sensitivity of fluorescent reporters, and noise in low-abundance regulatory molecules. |
| 2.2 Measurement Systems | Units | Standardized quantifications (meters, seconds, volts, decibels, dollars, etc.) necessary for consistent comparison. | Concentration (nM–µM), fluorescence intensity, phosphorylation percentage, DNA-damage foci counts, cell-cycle phase durations (minutes–hours), caspase activity units, chromatin-modification levels, gene-expression fold change. |
| | Instruments | Devices and tools (microscopes, spectrometers, sensors, surveys, detectors) used to produce measurements. | Flow cytometers, fluorescence microscopes, confocal and super-resolution imaging, time-lapse live-cell platforms, Western blotting, phospho-proteomics (mass spec), RNA-seq, ATAC-seq, apoptosis detection kits, TUNEL assays, cell-cycle reporter systems (FUCCI). |
| 2.3 Operational Definitions | Definitions | Terms defined by specific measurement procedures, ensuring empirical clarity. | Phase identity defined by FUCCI reporter signal or cyclin levels; apoptosis defined by caspase activation or phosphatidylserine externalization; senescence defined by SA-β-gal staining; DNA damage defined by γH2AX foci; differentiation defined by lineage-marker expression. |
| | Procedures | The explicit steps required to perform a measurement in a reproducible way. | Cell-cycle reporter imaging; caspase-activity assays; Annexin V staining; TUNEL labeling; chromosome spread preparation; phospho-protein blotting; flow cytometry gating for cell-cycle phase; lineage-marker staining; ATAC-seq or RNA-seq workflows. |
| 2.4 Data Acquisition | Protocols | Formal processes for gathering data under controlled or standardized conditions. | Standardized staining or reporter-expression conditions; controlled cell synchronization; fixed imaging intervals; repeated sampling across cycle phases; parallel control groups; consistent growth conditions; technical replicates for destructive assays. |
| | Sampling | Rules determining which subset of the domain is measured and how representative it is. | Selection of representative cells or populations; sampling across multiple cycle phases; capturing rare events (mitotic errors, apoptosis onset); avoiding bias in lineage-state sampling; adequate cell numbers for stochastic fate distributions. |
| 2.5 Data Character & Format | Data Types | The form raw evidence takes (time series, spectra, images, counts, qualitative records). | Time-lapse image sequences, flow-cytometry histograms, Western band intensities, phosphoproteomics spectra, transcriptomics matrices, chromatin-accessibility maps, apoptotic-marker distributions, quantitative foci counts. |
| | Resolution | The granularity or precision with which data is captured. | Spatial resolution dictated by microscopy method; temporal resolution from ms (checkpoint signaling) to hours (phase transitions); detection threshold set by sensor sensitivity; sequencing depth determines gene/chromatin resolution. |
| 2.6 Reliability & Calibration | Calibration | Adjustment procedures ensuring instruments produce accurate results. | Fluorescent reporter calibration, flow-cytometer voltage and compensation settings, mass-spec calibration, antibody validation, synchronization-effect checks, TUNEL/Annexin V control validation, microscope drift correction. |
| | Error Characterization | Identification and quantification of noise, uncertainty, bias, and measurement error. | Identifying artifacts from overexpression of reporters, synchronization-induced stress, photobleaching, gating errors, sequencing biases, sample fixation artifacts, cross-reactive antibodies, imaging drift, and quantifying random vs systematic error. |
| 3. Structural Layer | 3.1 Patterns & Regularities | Laws / Relations | Stable, repeatable patterns governing how observables behave across conditions. | Cell-cycle progression follows ordered, irreversible phase transitions (G1→S→G2→M); cyclin–CDK oscillations govern timing; DNA damage triggers checkpoint-induced arrest; apoptosis follows conserved activation logic; lineage commitment emerges from stable transcription-factor network motifs. |
| | Invariants | Quantities or properties that remain constant under transformations (symmetries, conservation laws). | Fixed order of phase transitions; conserved spindle-assembly rules; invariant apoptotic cascade architecture; stable lineage-determining transcription-factor interactions; constant stoichiometry of CDK–cyclin complexes; preserved chromatin-state landmarks across differentiation trajectories. |
| 3.2 Causal Architecture | Mechanisms | Underlying processes or structures that produce the observed regularities. | Cyclin synthesis/degradation drives cell-cycle transitions; checkpoints sense DNA integrity and spindle attachment; transcription-factor circuits determine lineage state; caspase cascades execute apoptosis; mitochondrial permeabilization commits the cell to death; senescence arises from persistent DNA damage and chromatin remodeling. |
| | Pathways | Organized sequences of interactions forming a causal chain or network. | G1/S transition pathway (cyclin D/E → CDK2 activation); DNA-damage response (ATM/ATR → p53 → arrest/apoptosis); mitotic entry and spindle checkpoint; intrinsic apoptotic pathway (BCL-2 family → MOMP → caspases); differentiation cascades (Notch, Wnt, MAPK → lineage transcription factors). |
| 3.3 Theoretical Vocabulary | Concepts | Core terms that encode the domain’s structure (force, gene, equilibrium, field). | Checkpoints, oscillators, bistability, irreversibility, lineage priming, commitment, chromatin remodeling, apoptosis threshold, senescence induction, replication licensing, spindle tension, caspase cascade, mitochondrial outer-membrane permeabilization. |
| | Classifications | Taxonomies, categories, or typologies that organize entities and relations. | Cell-cycle categories (G1, S, G2, M); death modalities (apoptosis, necroptosis, autophagic cell death); fate states (stem, progenitor, differentiated, senescent); checkpoint types (G1/S, intra-S, G2/M, spindle); lineage-decision structures (binary switches, graded responses, stochastic biases). |
| 3.4 Formal Representations | Equations | Mathematical constructs expressing laws, relations, or mechanisms. | ODE systems representing cyclin–CDK oscillators; threshold equations for checkpoint activation; bistability equations for lineage-fate transitions; caspase activation kinetics; Hill functions describing transcription-factor cooperativity; models of DNA-damage accumulation and repair rates. |
| | Models | Structured representations—mathematical, computational, or conceptual—used to predict and explain phenomena. | Cell-cycle oscillator models; stochastic models of checkpoint activation; apoptosis cascade models; lineage-decision network models; chromatin-state transition models; population-level proliferation–death balance models; agent-based models of differentiation or senescence. |
| 3.5 Idealized Structures | Simplified Models | Purposeful abstractions that capture essential dynamics while omitting irrelevant detail. | Phase-based cycle representation; binary fate decisions; apoptosis as an instantaneous switch; linearized checkpoint behavior; ignoring spatial heterogeneity or multi-step chromatin transitions; reducing death pathways to a single cascade. |
| | Limit Conditions | Regimes where specific models or approximations hold (classical vs. quantum, linear vs. nonlinear). | Idealizations fail when cycles overlap or stall, when fate decisions are probabilistic rather than binary, when death pathways interact or hybridize, when chromatin states exhibit high heterogeneity, or when noise in DNA damage overwhelms deterministic checkpoint logic. |
| 3.6 Integrative Frameworks | Unifying Theories | Higher-order structures that connect disparate laws or mechanisms under a coherent whole. | A unified model of cellular decision-making: proliferation governed by oscillatory regulators; fate driven by transcription-factor network dynamics; death controlled by mitochondrial and caspase systems; all integrated through checkpoint surveillance and chromatin-state regulation. |
| | Interdisciplinary Links | Points where the theory connects to adjacent sciences or larger explanatory systems. | Links to systems biology (oscillators, bistability), cancer biology (cell-cycle dysregulation, apoptosis evasion), immunology (death signaling), developmental biology (lineage commitment), aging research (senescence), and biophysics (chromatin mechanics, checkpoint kinetics). |
| 4. Method Layer | 4.1 Inquiry Design | Experimental Design | Structured plans for manipulating variables to test causal claims. | Perturbing cyclins/CDKs, inducing DNA damage, inhibiting checkpoint pathways, modulating transcription-factor levels, blocking apoptotic machinery, altering mitochondrial integrity, or shifting chromatin state to determine causal effects on cell-cycle progression, lineage commitment, or death initiation. |
| | Observational Design | Systematic approaches for gathering non-manipulated data (surveys, field studies, natural experiments). | Tracking unperturbed cell-cycle oscillations, endogenous differentiation trajectories, spontaneous apoptosis or senescence events, natural checkpoint activation, and native chromatin-state transitions without imposed interventions. |
| 4.2 Testing & Validation | Hypothesis Testing | Procedures for evaluating whether evidence supports or contradicts specific claims. | Testing predictions of phase timing, checkpoint arrest, differentiation outcomes, or apoptosis thresholds; validating kinetic models; verifying that perturbations produce expected cell-cycle delays, lineage changes, or death signatures. |
| | Replication | The requirement that results be independently reproducible under similar conditions. | Repeating cell-cycle reporter measurements, DNA-damage assays, apoptosis quantification, lineage-marker expression studies, and chromatin-state analyses across multiple replicates, conditions, and timepoints. |
| 4.3 Inference & Evaluation | Statistical Inference | Rules for drawing conclusions from noisy or incomplete data. | Estimating variability in cycle-phase durations, quantifying confidence in fate distributions, determining significance of changes in caspase activity or chromatin accessibility, inferring transition probabilities across lineage states. |
| | Model Comparison | Criteria (fit, simplicity, predictive accuracy, robustness) used to evaluate competing models. | Comparing cell-cycle oscillator models, fate decision-switch models, apoptosis cascade models, and chromatin-state transition models based on fit, predictive power, robustness to noise, and mechanistic coherence. |
| 4.4 Error Management | Error Analysis | Identification and quantification of random and systematic errors. | Identifying artifacts from synchronization methods, reporter overexpression, photobleaching, assay sensitivity limits, fixation artifacts, gating errors, and sequencing biases; partitioning random vs systematic error. |
| | Bias Control | Methods for minimizing subjective, instrumental, or procedural biases. | Standardizing synchronization protocols, controlling reporter expression, blinding data scoring, calibrating antibody specificity, normalizing imaging conditions, and validating lineage or death markers across platforms. |
| 4.5 Adjudication & Revision | Peer Scrutiny | Collective evaluation of claims through critique, review, and debate. | Reviewing interpretations of cell-cycle arrest, lineage trajectories, apoptosis/necrosis mechanisms, chromatin-state transitions, and checkpoint behaviors through internal review, peer review, and replication efforts. |
| | Theory Revision | Procedures for modifying, replacing, or discarding models based on new evidence. | Updating models when new evidence reveals alternative checkpoint logic, hybrid death pathways, atypical lineage bifurcations, or chromatin remodeling modes; revising oscillatory or bistable frameworks accordingly. |
| 4.6 Integrity Conditions | Transparency | Requirements to disclose methods, data, assumptions, and limitations. | Detailed reporting of perturbation methods, synchronization steps, imaging parameters, assay conditions, data-processing pipelines, normalization strategies, and all analytical assumptions and limitations. |
| | Ethical Standards | Norms ensuring responsible conduct in experimentation, data handling, and publication. | Ensuring responsible use of gene-editing tools and cell models, accurate reporting of death or differentiation outcomes, avoidance of selective data omission, and adherence to ethical standards for manipulating cellular life/death processes. |